Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
November 04, 2024 16:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient...
Dyadic Expands Global Presence with Participation in Key Industry Events
October 09, 2024 08:00 ET
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the large-scale, efficient manufacturing of...
Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference
September 23, 2024 09:50 ET
|
Dyadic International, Inc.
JUPITER, Fla., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient,...
Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
August 13, 2024 16:05 ET
|
Dyadic International, Inc.
Alternative Proteins Entered into a development and commercialization partnership for the sale of animal-free recombinant albumin products with Proliant Health and BiologicalsEntered into a joint...
Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024
July 30, 2024 16:00 ET
|
Dyadic International, Inc.
JUPITER, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient...
Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership
June 28, 2024 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., June 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), announced today that they have entered into a development and commercialization partnership...
Dyadic to Attend Industry Events in June
May 30, 2024 16:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of...
Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 14, 2024 16:00 ET
|
Dyadic International, Inc.
Human Health Sector Final Clinical Study Report has been issued for the First-In-Human Phase 1 clinical trial demonstrating safety and antibody response for DYAI-100, a recombinant...
Dyadic to Attend Industry and Investor Events in May
May 08, 2024 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
April 30, 2024 16:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient...